(Reuters) -The European Medicines Agency (EMA) said on Tuesday it was extending the review of Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda after reports of possible suicidal thoughts following usage, to include other drugs in the same class.
The agency began its review on July 3 after Iceland’s health regulator flagged three cases of patients thinking about suicide or self-harm following use of Novo’s drugs.
The EMA will now investigate drugs in the same class, known as GLP-1 receptor agonists, which trigger a feeling of fullness for possible risk of suicidal thoughts.
The review is expected to complete in November, said EMA.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
